Loading…
BCG vaccine: Worrying proposal for COVID-19
Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be fr...
Saved in:
Published in: | Vaccine 2021-01, Vol.39 (3), p.460-462 |
---|---|
Main Authors: | , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3 |
---|---|
cites | cdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3 |
container_end_page | 462 |
container_issue | 3 |
container_start_page | 460 |
container_title | Vaccine |
container_volume | 39 |
creator | Sarinho, Emanuel Goudouris, Ekaterini Solé, Dirceu |
description | Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity. |
doi_str_mv | 10.1016/j.vaccine.2020.12.026 |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7745307</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X20315930</els_id><sourcerecordid>2474462057</sourcerecordid><originalsourceid>FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</originalsourceid><addsrcrecordid>eNqFkctKAzEUhoMotlYfQRlwI8jUXGcSF4pWrYVCN952Ic1kNGU6qcm00Lc3pbWoG1eBk-98yfkPAMcIdhFE2cWku1Ba29p0McSxhrsQZzugjXhOUswQ3wXtWKEpRfCtBQ5CmEAIGUFiH7QIIRQRyNrg_LbXTzamy-TVeb-09Xsy827mgqqS0vmkN3oZ3KVIHIK9UlXBHG3ODnh-uH_qPabDUX_QuxmmmgrWpCLTHGdaCaOQYlwwRlUBiUaiKLimY6OoopxxQ3GZU6HJOGMMlqpEXBSQa9IBV2vvbD6emkKbuvGqkjNvp8ovpVNW_r6p7Yd8dwuZ55QRmEfB2Ubg3efchEZObdCmqlRt3DxITHPECOc5jejpH3Ti5r6O460oSjMM2UrI1pT2LgRvyu1nEJSrdciJ3IQoV-uQCMsYfuw7-TnJtus7_whcrwET81xY42XQ1tTaFNYb3cjC2X-e-AJBvpwQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2474462057</pqid></control><display><type>article</type><title>BCG vaccine: Worrying proposal for COVID-19</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Sarinho, Emanuel ; Goudouris, Ekaterini ; Solé, Dirceu</creator><creatorcontrib>Sarinho, Emanuel ; Goudouris, Ekaterini ; Solé, Dirceu</creatorcontrib><description>Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2020.12.026</identifier><identifier>PMID: 33341305</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adaptive immunity ; Age ; Bacillus Calmette-Guerin vaccine ; BCG ; BCG Vaccine ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Drug dosages ; Epidemiology ; Epigenetics ; Humans ; Hypotheses ; Immunity ; Immunization, Secondary ; Immunodeficiency ; Infections ; Infectious diseases ; Innate ; Mortality ; Pandemics ; Pneumonia ; Public health ; SARS-CoV-2 ; Scientific papers ; Severe acute respiratory syndrome coronavirus 2 ; Tuberculosis ; Tuberculosis - prevention & control ; Vaccines</subject><ispartof>Vaccine, 2021-01, Vol.39 (3), p.460-462</ispartof><rights>2020 Elsevier Ltd</rights><rights>Copyright © 2020 Elsevier Ltd. All rights reserved.</rights><rights>2020. Elsevier Ltd</rights><rights>2020 Elsevier Ltd. All rights reserved. 2020 Elsevier Ltd</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</citedby><cites>FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</cites><orcidid>0000-0002-1937-9124</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33341305$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sarinho, Emanuel</creatorcontrib><creatorcontrib>Goudouris, Ekaterini</creatorcontrib><creatorcontrib>Solé, Dirceu</creatorcontrib><title>BCG vaccine: Worrying proposal for COVID-19</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity.</description><subject>Adaptive immunity</subject><subject>Age</subject><subject>Bacillus Calmette-Guerin vaccine</subject><subject>BCG</subject><subject>BCG Vaccine</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Drug dosages</subject><subject>Epidemiology</subject><subject>Epigenetics</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Immunity</subject><subject>Immunization, Secondary</subject><subject>Immunodeficiency</subject><subject>Infections</subject><subject>Infectious diseases</subject><subject>Innate</subject><subject>Mortality</subject><subject>Pandemics</subject><subject>Pneumonia</subject><subject>Public health</subject><subject>SARS-CoV-2</subject><subject>Scientific papers</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Tuberculosis</subject><subject>Tuberculosis - prevention & control</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqFkctKAzEUhoMotlYfQRlwI8jUXGcSF4pWrYVCN952Ic1kNGU6qcm00Lc3pbWoG1eBk-98yfkPAMcIdhFE2cWku1Ba29p0McSxhrsQZzugjXhOUswQ3wXtWKEpRfCtBQ5CmEAIGUFiH7QIIRQRyNrg_LbXTzamy-TVeb-09Xsy827mgqqS0vmkN3oZ3KVIHIK9UlXBHG3ODnh-uH_qPabDUX_QuxmmmgrWpCLTHGdaCaOQYlwwRlUBiUaiKLimY6OoopxxQ3GZU6HJOGMMlqpEXBSQa9IBV2vvbD6emkKbuvGqkjNvp8ovpVNW_r6p7Yd8dwuZ55QRmEfB2Ubg3efchEZObdCmqlRt3DxITHPECOc5jejpH3Ti5r6O460oSjMM2UrI1pT2LgRvyu1nEJSrdciJ3IQoV-uQCMsYfuw7-TnJtus7_whcrwET81xY42XQ1tTaFNYb3cjC2X-e-AJBvpwQ</recordid><startdate>20210115</startdate><enddate>20210115</enddate><creator>Sarinho, Emanuel</creator><creator>Goudouris, Ekaterini</creator><creator>Solé, Dirceu</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1937-9124</orcidid></search><sort><creationdate>20210115</creationdate><title>BCG vaccine: Worrying proposal for COVID-19</title><author>Sarinho, Emanuel ; Goudouris, Ekaterini ; Solé, Dirceu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adaptive immunity</topic><topic>Age</topic><topic>Bacillus Calmette-Guerin vaccine</topic><topic>BCG</topic><topic>BCG Vaccine</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Drug dosages</topic><topic>Epidemiology</topic><topic>Epigenetics</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Immunity</topic><topic>Immunization, Secondary</topic><topic>Immunodeficiency</topic><topic>Infections</topic><topic>Infectious diseases</topic><topic>Innate</topic><topic>Mortality</topic><topic>Pandemics</topic><topic>Pneumonia</topic><topic>Public health</topic><topic>SARS-CoV-2</topic><topic>Scientific papers</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Tuberculosis</topic><topic>Tuberculosis - prevention & control</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sarinho, Emanuel</creatorcontrib><creatorcontrib>Goudouris, Ekaterini</creatorcontrib><creatorcontrib>Solé, Dirceu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sarinho, Emanuel</au><au>Goudouris, Ekaterini</au><au>Solé, Dirceu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>BCG vaccine: Worrying proposal for COVID-19</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2021-01-15</date><risdate>2021</risdate><volume>39</volume><issue>3</issue><spage>460</spage><epage>462</epage><pages>460-462</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Bacille Calmette-Guérin (BCG) vaccine is proven to be effective in protecting against severe tuberculosis. It has been suggested to be able to exert a non-specific beneficial effect as protection against other infectious diseases. The duration of protection against tuberculosis is estimated to be from 10 to 15 years, but the duration of the protection against other infections is not known, maybe up to 20 years, maybe much shorter than that. We don’t know it for sure. BCG induced trained immunity paradigm is based on experimental models, cohort studies with low number of individuals, and some epidemiological data in which other possible interfering factors are not controlled. The titles and scopes of scientific articles should be cautiously considered as they can promote indications of getting vaccinated or revaccinated with BCG, before its effectiveness is confirmed and recommendations are published. Besides, revaccination with BCG can put at serious risk patients with primary or secondary immunodeficiency. Maybe BCG vaccine is effective in preventing COVID-19 deaths or reducing its severity, but may the effect of this vaccine be relevant even with poor health politics and assistance? It is very difficult to compare the epidemiologic data about COVID-19 in different countries. There are countless factors, mainly social and related to the healthcare system, which can be more decisive than the hypothesis of trained immunity induced by BCG. Until now, we can say that BCG’s protective role is, at least, insufficient, given many other factors that corroborate SARS-CoV-2 infection and/or its severity.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>33341305</pmid><doi>10.1016/j.vaccine.2020.12.026</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0002-1937-9124</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2021-01, Vol.39 (3), p.460-462 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7745307 |
source | ScienceDirect Freedom Collection 2022-2024 |
subjects | Adaptive immunity Age Bacillus Calmette-Guerin vaccine BCG BCG Vaccine Coronaviruses COVID-19 COVID-19 vaccines Drug dosages Epidemiology Epigenetics Humans Hypotheses Immunity Immunization, Secondary Immunodeficiency Infections Infectious diseases Innate Mortality Pandemics Pneumonia Public health SARS-CoV-2 Scientific papers Severe acute respiratory syndrome coronavirus 2 Tuberculosis Tuberculosis - prevention & control Vaccines |
title | BCG vaccine: Worrying proposal for COVID-19 |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T20%3A50%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=BCG%20vaccine:%20Worrying%20proposal%20for%20COVID-19&rft.jtitle=Vaccine&rft.au=Sarinho,%20Emanuel&rft.date=2021-01-15&rft.volume=39&rft.issue=3&rft.spage=460&rft.epage=462&rft.pages=460-462&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2020.12.026&rft_dat=%3Cproquest_pubme%3E2474462057%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c495t-96c826ca9ea1a589554ad03c19dd8c4bea4a4858e42f749c3b6550faf189d08c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2474462057&rft_id=info:pmid/33341305&rfr_iscdi=true |